Novavax Inc NVAX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/16/21 EDT
225.50quote price arrow down-1.85 (-0.81%)
Volume
77,006
Close
227.35quote price arrow up+25.26 (+12.50%)
Volume
4,412,034
52 week range
16.41 - 331.68

...

Loading . . .
  • Open201.71
  • Day High228.10
  • Day Low200.50
  • Prev Close202.09
  • 52 Week High331.68
  • 52 Week High Date02/09/21
  • 52 Week Low16.41
  • 52 Week Low Date05/01/20

Key Stats

  • Market Cap16.792B
  • Shares Out73.86M
  • 10 Day Average Volume2.64M
  • Dividend-
  • Dividend Yield-
  • Beta1.46
  • YTD % Change103.88

KEY STATS

  • Open201.71
  • Day High228.10
  • Day Low200.50
  • Prev Close202.09
  • 52 Week High331.68
  • 52 Week High Date02/09/21
  • 52 Week Low16.41
  • 52 Week Low Date05/01/20
  • Market Cap16.792B
  • Shares Out73.86M
  • 10 Day Average Volume2.64M
  • Dividend-
  • Dividend Yield-
  • Beta1.46
  • YTD % Change103.88

RATIOS/PROFITABILITY

  • EPS (TTM)-6.79
  • P/E (TTM)-33.50
  • Fwd P/E (NTM)11.67
  • EBITDA (MRQ)-415.734M
  • ROE (MRQ)-189.60%
  • Revenue (MRQ)475.60M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-87.94%
  • Debt To Equity (MRQ)74.61%

EVENTS

  • Earnings Date05/08/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates...
James Young Ph.D.
Chairman
Stanley Erck
President
Rick Crowley
Chief Operating Officer
Gregory Covino
Chief Financial Officer
Ben Machielse
Executive Vice President
Address
21 Firstfield Rd
Gaithersburg, MD
20878-1757
United States